Fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral DTIs showed no clear difference in fatal PE (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Non‐fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral DTIs showed no clear difference in non‐fatal PE (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality (7 months) · participants with diagnosed DVT
Oral DTIs showed no clear difference in all‐cause mortality (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Major bleeding · participants with diagnosed DVT
Oral DTIs leads to lower major bleeding (7 months) compared with conventional anticoagulation (high certainty).
1 finding from 1 review
Intervention not reported
Proportion of participants with success, defined as 0 to trace cells or 2‐step decrease in activity SUN‐grading ( · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
The intervention showed no clear difference in proportion of participants with success, defined as 0 to trace cells… (low certainty).
1 finding from 1 review
Intervention not reported
Risk of failure defined as 2‐step increase in activity in SUN grading ( · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
The intervention showed no clear difference in risk of failure defined as 2‐step increase in activity in SUN… (low certainty).
1 finding from 1 review
Intervention not reported
Risk of recurrence and mean time‐to‐recurrence after induction of remission at 2 or 6 months · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Mean change from baseline in logMAR visual acuity at 6 months*2 · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
1 finding from 1 review
Intervention not reported
Mean change from baseline in number of topical or systemic steroids at 6 months*2 · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Frequency and nature of adverse effects · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
1 finding from 1 review
Intervention not reported
Stroke and other systemic embolic events · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower stroke and other systemic embolic events (high certainty).
1 finding from 1 review
Intervention not reported
All strokes · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower all strokes (high certainty).
1 finding from 1 review
Intervention not reported
Major bleedings · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention probably leads to lower major bleedings (moderate certainty).
1 finding from 1 review
Intervention not reported
Intracranial haemorrhages · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower intracranial haemorrhages (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause deaths · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention probably leads to lower all‐cause deaths (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · people with metastatic colorectal cancer ‐ KRAS exon 2 WT
The intervention leads to lower progression‐free survival (high certainty).
1 finding from 1 review
Intervention not reported
Overall survival · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention showed no clear difference in overall survival (high certainty).
1 finding from 1 review
Intervention not reported
Tumour response rate · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention showed no clear difference in tumour response rate (high certainty).
1 finding from 1 review
Intervention not reported
Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
It is very uncertain whether the intervention changes overall grade 3 to 4 toxicity (very low certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention may leads to higher grade 3 to 4 diarrhoea (low certainty).
1 finding from 1 review